Thyroid nodule is a common medical problem with a prevalence of 1% to 5% by palpation and from 19% to 67% by high-resolution ultrasound (1-3). Deciding on whether to send a patient with a thyroid nodule to surgery or not depends mainly on fine-needle aspiration (FNA) biopsy results. A comparison of FNA cytology (FNAC) results against the gold standard, the histopathological diagnosis provides a measure of FNAC usefulness. Accurate FNAC assessment of thyroid nodules would prevent unnecessary surgery with its possible complications, including injury to the recurrent laryngeal nerve, hypoparathyroidism, and thyroid hormone dependence.
Due to the simplicity, accuracy, low cost, and absence of major complications of FNA biopsy, it is considered the most reliable method for the management of thyroid nodules and should be used as the main diagnostic test (4,5). Retrospective studies have reported lower rates of both non-diagnostic and false-negative cytology specimens from FNA procedures performed under ultrasound guidance compared with palpation (6-8). The American Thyroid Association recommends FNAC as the main diagnostic test for thyroid nodules because of its superior diagnostic reliability and cost effectiveness (3).
Diagnostic accuracy of FNAC varies between different series and depends in a part on the method of data analysis. Sensitivity ranges between 55% and 83%, and specificity between 74% and 98%
(5,9-12) Skilled FNA technique and the availability of experienced cytologists are vital to achieving high diagnostic accuracy (8). Several diagnostic pitfalls have been described in the literature, including inadequate sampling, insufficient cellular material from cystic or hemorrhagic lesions, and limited experience of those who perform and interpret FNAC. Additionally, number of punctures and the smear preparation techniques also affect results (4,8).
Recently, The Bethesda classification system of FNAC results has been recommended to be uniformly used for reporting of FNAC (13). Limited number of studies has assessed the diagnostic usefulness of this system. Most of these studies came from the Western world. In this study, our objectives are not only to evaluate the overall accuracy of FNAC but also to evaluate this system in our practice.
A retrospective, medical chart review of patients who underwent thyroidectomy or hemithyroidectomy between July 2006 and June 2010 was conducted at King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. Data included patient characteristics, including age, sex, and size of the nodule by ultrasound, as well as histopathology, FNAC, and postoperative histopathological results.
Criteria for inclusion were availability of records of patients who underwent thyroidectomy or hemithyroidectomy between July 2006 and June 2010, had nodules larger than 1.5 cm along at least one axis (longitudinal, anterior-posterior, transverse), and had FNAC and histopathology reports approved by a qualified consultant cytopathologist. We excluded all cases with any of the following: nodule less than 1.5 cm on ultrasound, incomplete FNAC or histopathology report, or FNAC with no diagnostic or unsatisfactory findings.
Thyroid nodule FNA biopsy was done in the pathology department if the thyroid nodule was easily palpable. Ultrasound-guided FNA biopsy was done in the radiology department when the nodules were not palpable or were difficult to discriminate from normal thyroid tissue. 23 and 25 gauge needles were used, with 3 to 4 passes per nodule. Papanicolaou and Diff-Quik staining methods were used for slide preparation by a cytopathology technician before sending samples to the pathologist.
The reasons for hemi or total thyroidectomy were: non benign cytology results, compression symptoms, large nodules and patient preference.
FNAC results were categorized according the Bethesda system 13-15 as follows:
• Nondiagnostic or unsatisfactory, including limited cellularity, no follicular cells present, poor fixation, excessive blood, and/or poor cell preservation.
• Benign, which included nodular goiter, chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), hyperplastic/adenomatoid nodule, and colloid nodule.
• Atypia of undetermined significance or follicular lesion of undetermined significance where the cytologic findings were not convincingly benign, yet the degree of cellular or architectural atypia was insufficient for an interpretation of follicular neoplasm, Hürthle cell neoplasm, or suspicious for malignancy.
• Follicular neoplasm or suspicious for follicular neoplasm, including nonpapillary follicular-patterned lesions/neoplasms and Hürthle cell lesions/neoplasms.
• Suspicious for malignancy including suspicious for papillary thyroid carcinoma (PTC), suspicious for medullary thyroid carcinoma (MTC), or suspicious for other primary or secondary malignancy.
• Malignant including PTC, follicular thyroid carcinoma (FTC), MTC, Hürthle cell carcinoma (HCC), anaplastic carcinoma, or metastatic carcinoma.
FNAC results that were nondiagnostic or unsatisfactory and continued to be the same after repeating FNA were excluded from the analysis.
When we measured the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPP), and accuracy of FNAC, we labeled benign FNAC results as negative. PTC or suspicion of PTC was labeled as positive since both are indications for surgery. The histopathology report was considered negative if the result was benign and positive if the result was PTC. All FNAC false negative and false positive results were re-evaluated and confirmed. FNAC results of atypia of undetermined significance or follicular lesion of undetermined significance, and follicular neoplasm or suspicious for follicular neoplasm were evaluated separately. Histopathology report of MTC and HCC were excluded due to a small number of cases (n=2). FTC is a diagnosis that can only be made by histopathological examination, and it is almost impossible to do by FNAC; for that reason, FTC cases were not included in the analysis. Incidental findings of micro-PTC (defined as lesions <1 cm) outside the targeted nodule were not included as a positive result because micro-PTC is difficult to diagnose by FNA due to its small size and overall benign course (3).
Each FNAC diagnosis was matched to the histopathological result and labeled as follows: (1) true positive-positive result in the FNAC (i.e., PTC or suspicion of PTC) confirmed in the histological study; (2) false positive-positive result in the FNAC but not histologically confirmed; (3) true negative-negative result in the FNAC (i.e., benign) and no carcinoma in the histological study; and (4) false negative-negative result in the FNAC but with a PTC revealed in histological study. Sensitivity was the proportion of patients with PTC and a positive result in the FNAC. The formula used for sensitivity was S=TP/(TP+FN), where S=sensitivity, TP=true positive, and FN=false negative. Specificity was the proportion of patients without PTC but a positive result from FNAC. The formula for specificity was SP=TN/(TN+FP), where SP=specificity, TN=true negative, and FP=false positive. Positive predictive value (PPV) was the proportion of patients with a positive result and histological confirmation, and the formula was PPV=TP/(TP+FP). Negative predictive value (NPV) was the proportion of patients with negative results and without PTC in the histological study, and the formula was NPV=TN/(TN+FN). Finally, diagnostic accuracy (DA) was the proportion of patients correctly diagnosed by FNAC, and the formula was DA=(TP+TN)/(FP+FN+TP+TN).
All data were verified prior to encoding into Microsoft Excel 2007 worksheet. Statistical analyses were done using Predictive Analysis Software version 18.0 (SPSS, IBM, Chicago, Illinois). Data were presented as mean, standard deviation, and percentage distribution. Categorical correlations were done using chi-square test and continuous variables by independent t-test. Calculations of specificity, sensitivity, PPV, and NPV were done using the formulas stated above.
A total of 275 patients with thyroid FNAC and final histopathology specimens were reviewed and analyzed. The mean age of the patients was 38.5±12.6 years (range: 14-90 years). Two hundred forty specimens (87.6%) were from the female patients, and 35 (12.4%) were from the male patients. See table 1 for the details of cytology results and histopathological diagnosis.
The histological diagnosis of 179 patients with benign FNAC included 159 (88.8%) benign lesions, 10 (5.6%) PTCs, of which 9 (90%) of the nodules were large (>3.8 cm) and 1 lesion was 2.2 cm. Nine cases (5.0%) were micro-PTC and 1 (0.6%) was FTC. Of the 60 FNAC cases of atypia of undetermined significance or follicular lesion of undetermined significance, 38 (63.3%) were benign, 10 (16.7%) were PTC, 8 (13.3%) were micro-PTC, 3 (5.0%) were FTC, and 1 (1.7%) was MTC. Of 15 cases diagnosed as follicular neoplasm or suspicious of a follicular neoplasm by FNAC, 6 (40.0%) were benign by histopathology, 4 (26.7%) were PTC, 3 (20.0%) were FTC, 1 (6.7%) was micro-PTC, and 1 (6.7%) was HCC. Of the 6 cases suspicious for PTC by FNAC, 1 (16.7%) turned out to be benign by histopathology, and the remaining 5 cases (83.3%) were PTCs. Of the 15 FNAC cases that were consistent with PTC, all turned out to be PTC by histopathology (Table 1).
The analysis of diagnostic accuracy including sensitivity, specificity, PPV, and NPV included a total of 190 cases as we labeled benign FNAC results as negative, PTC or suspicion of PTC was labeled as positive other FNA results were excluded. We excluded 9 micro-PTC cases and one FTC case from benign FNAC group and end by 169 cases. We included 15 FNAC cases with PTC and 6 cases with suspicious of PTC results. Our study yielded 20 true-positive results, 1 false-positive result, 10 false-negative results, and 195 true-negative results. 9 out of 10 false negative results were for nodules size between 3.8 to 6 cm, and one 2.1 cm.
Analysis of the FNAC results obtained were compared with the histological findings in order to rule out malignancy yielded a sensitivity (95% CI) of 66.7% (60.5% to 74.1%), specificity of 99.4% (97.5% to 100%), PPV of 95.2% (91.1% to 97.9%), NPV of 94.1% (90.9% to 97.7%), and a diagnostic accuracy of 94.2% (90.8% to 97.6%) (Table 2).
The literature reports FNAC sensitivity ranging between 55% and 83%, and specificity between 74% and 98%.9-10 Our study yielded a sensitivity of 66.7% with a high specificity, PPV, NPV, and diagnostic accuracy (99.4%, 95.2%, 94.1%, and 94.2%, respectively), which is in accordance with values reported in the literature (5,9-11). In contrast to the number of false negatives, the number of false positives was very low (n=1). FNAC provides a diagnosis of PTC with high confidence. Any patients with an FNAC result consistent with PTC or suspicious for PTC should be referred for surgery, and the initial surgery is usually total thyroidectomy. However, the decision is influenced by the evaluation of the patient’s clinical status, the size and aggressiveness of the PTC, and whether radioiodine ablation is planned (3,15).
Our study showed 10 cases of false-negative FNAC results, which may have lowered the sensitivity of the result (66.7%). The majority of these false negatives (9 out of 10) were nodules larger than 3.8 cm in size (3.8 to 6 cm). Although false-negative results in FNAC can be due to sampling error or misinterpretation of cytology slides, the rate of false-negative FNAC reports ranges from 1% to 31% (16,17). Some studies reported an increase in the false-negative rate with larger-sized thyroid nodules (8,19).
The rate of FNAC results of atypia of undetermined significance or follicular lesion of undetermined significance was 21.8%, this should be minimized to represent only 7% of all thyroid FNA biopsy interpretations (14). In our report, the percentage of PTC from this category was 23.3%, which is higher than the reported percentage, which lies between 5% and 10%.13,19 In patients with an FNAC result of atypia of undetermined significance or follicular lesion of undetermined significance, an 123I scan may be considered if the serum thyrotropin (TSH) level is within the low or low-normal range (normal range, 0.25 to 5.0 IU/mL) 3 . If the scan shows a hot nodule, clinical follow-up with repeat FNA biopsy in 3 to 6 months is appropriate. If the scan shows a cold nodule, the patient should be referred for surgery. If the TSH level is high or high-normal, patients should be advised to repeat FNA biopsy in 3 months, and if FNAC repeatedly shows the same result, patients should be advised to undergo surgery because a significant proportion of them eventually harbor malignancy (15).
In 26.7% of FNAC cases with follicular neoplasm or suspicion of follicular neoplasm, PTC was diagnosed, which agrees with values reported in the literature (13,19,20). A referral for operative exploration is recommended in such cases; usually, a hemi-thyroidectomy or lobectomy is performed, followed by histologic examination for capsular and vascular invasion to distinguish between follicular adenoma and follicular carcinoma (13,15).
There were 7 cases of FTC. One arose from nodules with benign FNAC, 3 had atypia or follicular lesion by FNAC, and 3 had follicular neoplasm or suspicious for a follicular neoplasm by FNAC. In two cases, one was HCC and the other one was MTC, and both had an FNAC finding of follicular neoplasm. HCC and MTC are rare entities. A high index of suspicion coupled with a careful investigation by clinicians and pathologists is needed to make a diagnosis of MTC (21).
Summary and Recommendation
FNAC as a screening tool for the diagnosis of thyroid nodules had very high diagnostic accuracy (94.2%) in our report and concurred with the standards and the published literature. FNAC should be performed and interpreted by individuals who have adequate training and experience in performing thyroid biopsy and slide preparation and in reading cytology slides to avoid false negative results. Due to a high proportion of false-negative FNAC results of the large nodules, they may be considered for surgical removal in the presence of other high risk features.
Address for Correspondence/Yazışma Adresi: Anwar Jammah MD, King Saud University, Medicine, Riyadh, Saudi Arabia
Phone: +96614691511 E-mail: firstname.lastname@example.org Recevied/Geliş Tarihi: 09.05.2012 Accepted/Kabul Tarihi: 30.06.2012
1. Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med 1992;93:359-62.
2. Rojeski MT, Gharib H. Nodular thyroid disease. Evaluation and management. N Engl J Med 1985;313:428-36.
3. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–42.
4. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc 1994;69:44-9.
5. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993;118:282-9.
6. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998;8:15–21.
7. Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 1998;8:283–9.
8. Ogawa Y, Kato Y, Ikeda K, et al. The value of ultrasound guided fine-needle aspiration cytology for thyroid nodules: an assessment of its diagnostic potential and pitfalls. Surg Today 2001;31:97-101.
9. Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 2003;186:702-10.
10. Kuru B, Gulcelik NE, Gulcelik MA, Dincer H. The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules. Langenbecks Arch Surg 2010;395:127-32.
11. Chang HY, Lin JD, Chen JF, et al. Correlation of fine needle aspiration cytology and frozen section biopsies in the diagnosis of thyroid nodules. J Clin Pathol 1997;50:1005-9.
12. Lansford CD, Teknos TN. Evaluation of the thyroid nodule. Cancer Control 2006;13:89-98.
13. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425–37.
14. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009;19:1159-65.
15. Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99-110.
16. Hamaker RC, Singer MI, DeRossi RV, Shockley WW. Role of needle biopsy in thyroid nodules. Arch Otolaryngol 1983;109:225-8.
17. Radeti? M, Kralj Z, Padovan I. Reliability of aspiration biopsy in thyroid nodes: study of 2190 operated patients. Tumori 1984;70:271-6.
18. McCoy KL, Jabbour N, Ogilvie JB, et al. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007;142:837-844.
19. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and linical correlations. Cancer 2007;111:306-15.
20. Barbaro D, Simi U, Lopane P, et al. Thyroid nodules with microfollicular findings reported on fine-needle aspiration: invariably surgical treatment? Endocr Pract 2001;7:352-7.
21. Collins BT, Cramer HM, Tabatowski K, et al. Fine needle aspiration of medullary carcinoma of the thyroid. Cytomorphology, immunohistochemistry and electron microscopy. Acta Cytol 1995;39:920-30.